Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.41 |
| ▸ | BCHE | P06276 | 1/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
| ▸ | PTGES | O14684 | 1/20 | 0.40 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | PDE4A | P27815 | 1/20 | 0.38 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.38 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12702768 | 0.86 | RAB9A (0.48) | RAB9ASMN1; SMN2PTPN1KDM4EHPGD | |
| SCHEMBL4623926 | 0.82 | PDE4A (0.40) | RAB9AKDM4ETP53NPC1PDE4A | |
| SCHEMBL10144993 | 0.81 | NPC1 (0.43) | RAB9ASMN1; SMN2KDM4EBCHEPTGES | |
| SCHEMBL18124437 | 0.79 | OPRM1 (0.53) | RAB9ASMN1; SMN2BCHEMEN1MAPT | |
| SCHEMBL642956 | 0.79 | SMN1; SMN2 (0.48) | RAB9ASMN1; SMN2KDM4EHPGDMEN1 | |
| SCHEMBL28119107 | 0.76 | BCHE (0.55) | BCHEHTR2CMEN1MAPTKMT2A | |
| SCHEMBL10106337 | 0.74 | EGFR (0.41) | RAB9ASMN1; SMN2MAPTNPC1PDE4A | |
| SCHEMBL10106318 | 0.73 | EGFR (0.32) | RAB9ASMN1; SMN2NPC1PDE4APDE4B | |
| SCHEMBL9778943 | 0.72 | PDE4A (0.57) | SMN1; SMN2KDM4EBCHEMEN1KMT2A | |
| SCHEMBL9778687 | 0.72 | APP (0.55) | RAB9ASMN1; SMN2KDM4EHPGDMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9321739-B2 | Compounds, compositions and methods for treating or preventing pneumovirus infection and associated diseases | MICRODOSE THERAPEUTX, INC. (US) | 2016-04-26 | — | — | US | disclosed |
| US-9321739-B2 | Compounds, compositions and methods for treating or preventing pneumovirus infection and associated diseases | MICRODOSE THERAPEUTX, INC. (US) | 2016-04-26 | — | — | US | disclosed |
| US-8119672-B2 | Compounds, compositions and methods for treating or preventing pneumovirus infection and associated diseases | MICRODOSE THERAPEUTX, INC. (US) | 2012-02-21 | — | — | US | disclosed |
| US-8119672-B2 | Compounds, compositions and methods for treating or preventing pneumovirus infection and associated diseases | MICRODOSE THERAPEUTX, INC. (US) | 2012-02-21 | — | — | US | disclosed |
| US-20110305666-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING PNEUMOVIRUS INFECTION AND ASSOCIATED DISEASES | RYS DAVID J (US) | 2011-12-15 | — | — | US | disclosed |
| US-20110305666-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING PNEUMOVIRUS INFECTION AND ASSOCIATED DISEASES | RYS DAVID J (US) | 2011-12-15 | — | — | US | disclosed |
| US-20030092685-A1 | Compounds, compositions and methods for treating or preventing pneumovirus infection and associated diseases | NITZ THEODORE J (US) | 2003-05-15 | — | — | US | disclosed |
| US-6495580-B1 | A BENZYLIDENE DERIVATIVE CONTAINING HETEROCYCLIC RING IS USEFUL AS PNEUMOVIRUS INHIBITOR | VIROPHARMA INCORPORATED | 2002-12-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110305666-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING PNEUMOVIRUS INFECTION AND ASSOCIATED DISEASES | TTPA, HAVCR2, PML | RAB9A 2880/4885SMN1; SMN2 1044/4885PTPN1 3915/4885 |
| US-20030092685-A1 | Compounds, compositions and methods for treating or preventing pneumovirus infection and associated diseases | TTPA, HAVCR2, PML | RAB9A 2880/4885SMN1; SMN2 1044/4885PTPN1 3915/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.